<DOC>
	<DOCNO>NCT01389427</DOCNO>
	<brief_summary>This multicenter , open label , three arm , Phase IB study . A dose escalation phase Temsirolimus ( Torisel™ ) administer intravenous ( IV ) day 2 , day 8 day 15 combination three chemotherapy regimens patient relapsed/refractory Mantle Cell Lymphoma ( MCL ) : - Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone ( R-CHOP ) administer every 3 week 6 cycle , - Rituximab-Fludarabine-Cyclophosphamide ( R-FC ) administer every 4 week 6 cycle , - Rituximab-Aracytine high dose-Dexamethasone ( R-DHA ) administer every 4 week 6 cycle .</brief_summary>
	<brief_title>Escalating Doses Torisel Combination With Three Chemotherapies Regimens : R-CHOP , R-FC R-DHA Patients With Relapsed/Refractory Mantle Cell Lymphoma ( MCL ) .</brief_title>
	<detailed_description>This three arm trial investigates Temsirolimus ( Torisel™ ) combination three chemotherapy regimen ( R-CHOP , R-FC R-DHA ) . Primary Objective : - To assess feasibility three chemotherapy regimens combination Temsirolimus ( Torisel™ ) ass incidence dose limit toxicity ( DLT ) two first cycle Temsirolimus ( Torisel™ ) combination three chemotherapy regimen order determine maximal tolerate dose ( MTD ) dose escalate study design population patient relapsed/refractory Mantle Cell Lymphoma ( MCL ) . Secondary objective : - To assess safety association Temsirolimus three chemotherapy regimen , - To determine efficacy association Temsirolimus ( Torisel™ ) three chemotherapy regimens 4 cycle 6 cycle end treatment : response rate complete response rate ( CR ) , progression-free survival ( PFS ) , response duration ( RD ) overall survival ( OS ) . All subject receive least one dose Temsirolimus ( Torisel™ ) consider evaluable included safety analysis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Vidarabine Phosphate</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm refractory relapse Mantle Cell Lymphoma ( initial diagnosis relapse ) , 2 . Ann Arbor Stage IIV least one tumor site measurable , 3 . Patients receive prior therapy ( least one three line therapy ) Mantle Cell Lymphoma ( MCL ) , 4 . Aged ≥ 18 year , 5 . ECOG performance status 0 , 1 2 , 6 . Adequate hepatic renal function : Serum Glutamic Oxaloacetic Transaminase ( SGOT ) /AST Serum Glutamic Pyruvic TransaminaseSGPT/ALT ≤ 3.0 x upper limit normal ( ULN ) , Serum Total Bilirubin ≤ 1.5 mg/dL ( 26 μmol/L ) except case hemolytic anemia , Serum Creatinine ≤ 2 mg/dL ( 177 μmol/L ) calculate Creatinine Clearance ( CockcroftGault formula ) ≥ 50 mL /min 7 . Adequate bone marrow reserve : Absolute neutrophil count ( ANC ) ≥ 1 G/L ( 1,000 cells/mm³ ) Platelets count ≥ 50 G/L Hemoglobin ≥ 9.0 g/dL , 8 . Signed date inform consent , 9 . Life expectancy ≥ 90 day ( 3 month ) 1 . Other type lymphoma , e.g . Bcell lymphoma , 2 . Contraindication drug contain three chemotherapy regimen ( RCHOP , RFC , RDHA ) , 3 . Tested positive HIV , 4 . Active Hepatitis B and/or C , 5 . Exhibits evidence clinically significant uncontrolled condition ( ) include , limited , active systemic fungal infection , diagnosis fever neutropenia , 6 . Any serious active disease comorbid medical condition ( accord investigator 's decision ) , 7 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form , 8 . Received biological agent antineoplastic intent within 30 day prior first dose study drug , 9 . Use standard experimental anticancer drug therapy within 30 day prior first dose study drug , 10 . Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 3 year , 11 . Left Ventricular Ejection Fraction &lt; 45 % ( calculated echocardiographic scintigraphic method ) , 12 . Pregnancy breast feeding woman , 13 . Women childbearing potential willing use adequate method birth control duration study twelve month end treatment , 14 . Male patient whose sexual partner ( ) WOCBP willing use adequate contraception , study twelve month end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>